ISRG Intuitive Surgical NASDAQ $479.93 on 20 Mar 2026: FDA alert tests AI robotics upside

ISRG stock trades at $479.93 intraday on 20 Mar 2026, after a regulatory safety alert from the U.S. FDA introduced near-term pressure. Volume stands at 1,258,652 shares and market cap is $170.44B USD, highlighting investor focus on fundamentals and risk. We track earnings, technicals, and analyst price targets to show why AI-driven robotics growth still matters for Intuitive Surgical, Inc. (ISRG) on NASDAQ

Market snapshot and intraday moves for ISRG stock

ISRG (Intuitive Surgical, Inc.) opened at $477.50 and is trading between $475.81 and $483.04 today on NASDAQ. The one-day change is $2.20 or 0.46%, with average volume at 1,854,983. Key valuation metrics: PE 60.98, EPS $7.87, 50‑day average $510.39, 200‑day average $510.17. These figures explain why the stock remains expensive versus peers while still drawing strong institutional ownership.

Recent news: FDA safety alert and cybersecurity reports that moved ISRG stock

An FDA safety alert tied to a da Vinci component caused selling pressure and heightened regulatory risk this week. Investors also flagged a separate cybersecurity incident reported in sector coverage. Combined, those items created a short-term headwind for ISRG stock and raise monitoring points for hospitals that deploy da Vinci systems. For source detail see the Seeking Alpha report and related filings source and institutional ownership updates on MarketBeat source.

Earnings, growth and valuation: fundamentals behind ISRG stock

Intuitive reported solid results in January: revenue $2.87B and EPS $2.53 for the quarter, beating estimates. Trailing EPS is $7.87 and net margin is 28.38%. Revenue per share is 28.36 and free cash flow per share is 7.02. Growth metrics remain healthy—FY revenue growth 17.24%, operating cash flow growth 33.15%—but the high PE and price-to-sales of ~16.95 demand continued execution to justify multiples.

Technicals, momentum and sector context for ISRG stock

Technical indicators show the stock in a corrective phase: RSI 40.98, MACD histogram slightly negative, and ATR 13.38. Price sits under the 50‑day and 200‑day averages, indicating near-term downside risk. Healthcare and medtech trends remain constructive for robotic surgery adoption, but rotation into other AI robotics names can increase ISRG volatility. Traders should note Bollinger middle at 491.79 and lower band 471.95 as support references.

Meyka AI grade and model forecasts for ISRG stock

Meyka AI rates ISRG with a score of 79.68 out of 100 and assigns a B+ (BUY) suggestion. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects: monthly $438.35, quarterly $485.77, and yearly $585.45. Compared with the current price $479.93 USD, the model implies a +1.21% upside to the quarterly target and +21.99% to the yearly target. Forecasts are model-based projections and not guarantees.

Price targets, analyst consensus and risk checklist for ISRG stock

Street targets range from UBS $550.00 to Goldman Sachs $714.00, and MarketBeat shows an average target near $614.95. We frame practical targets: conservative $485.00, base $615.00, bull $714.00. Primary risks: FDA or product safety findings, cybersecurity exposure, and slower procedure growth. Key opportunities: expanding Ion lung diagnostics, recurring instrument revenue, and AI-enabled OR software that can lift long-term margins.

Final Thoughts

Short-term trading for ISRG stock is balancing a regulatory scare and still-strong fundamentals. At $479.93 USD intraday, the market is pricing a reset versus 50/200‑day averages near $510.39 and $510.17. Meyka AI’s forecast model projects a quarterly level of $485.77 and a one‑year projection of $585.45, implying +1.21% and +21.99% upside respectively versus today. Our view: the stock remains a growth‑at‑a‑premium idea tied to robotic adoption and software monetization, but investors should weigh regulatory headlines and high valuation multiples (PE 60.98) before adding exposure. Use conservative position sizing and monitor upcoming earnings and FDA communications. Meyka AI provides this analysis as an AI-powered market analysis platform; forecasts are model-based and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.